Effect of irbesartan in proteinuric non-diabetic renal disease;Efecto de irbesartán en patología renal proteinúrica no diabética

Nefrologia

Volumn 25, Issue 5, 2005, Pages 509-514

  De Gracia, M C ^a   Molina Núñez, Manuel ^a   Navarro, M J ^a   Garcia Hernandez M A ^a  

^a Servicio de Farmacia   (Spain)

Author keywords

Glomerulonephritis; Irbesartan; Nephroprotection; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; IRBESARTAN; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; TETRAZOLES;

EID: 33644856818     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997.
2. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57: 1803-1817, 2000.
3. Peterson JC, Adler S, Burkanrt JM y cols.: for de Modification of Diet in Renal Disease (MDRD) Study Group: blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123: 754-762, 1995.
4. Breyer JA, Bain RP, Evans JK y cols.: and The Collaborative Study Group: predictors of the progression of renal insuficiency in patients with insulin-dependent diabetes and overt diabetic nephopaty. Kidney Int 50: 1651-1658, 1996.
5. Keane W: Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 35: S97-S105, 2000.
6. Jafar TB, Stark PC, Schmid CH y cols.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140, 2001.
7. Brenner BM, Cooper ME, DeZeeuw D y cols.: for the Renal Study Investigators: effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
8. Parving HH, Lehnert H, Bröchner-Mortensen J y cols.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
9. Lewis EJ, Hunsicker LG, Clarke WR y cols.: for the Collabortive Study Group: renorpotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
10. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropahy. Lancet 349: 1857-1863, 1997.
11. Praga M, Andrade CF, Luño J y cols.: Antiproteinuric efficacy of losartan in comparison with amlodipine in no diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 18 (9): 1806-13, 2003.
12. Aros C, Remuzzi G: The renin-angiotensin system in progresion, remision and regresion of chronic nephropathies. J Hyperten 20 (Supl. 3): S45-S53, 2002.
13. Schieppati A, Remuzzi G: The future of renoprotection: frustratio and promises. Kidney Int 64: 1947-1955, 2003.
14. Praga M: Slowing the progression of renal failure. Kidney Int 61 (Supl. 80): S18-S22, 2002.
15. Perico N, Remuzzi A, Sangalli F y cols.: The Antiproteinuric Effect of Angiotensin Antagonism in Human IgA Nephropathy is Potenciated by Indomethacin. J Am Soc Nephrol 9: 2308-2317, 1998.
16. Sano T, Hotta N, Kawsamura T y cols.: Effect of long-term enalapril treatment on persistent microalbuminuria in normotensive type2 diabetic patients: result of 4-year, prospective randomized study. Diabetic Med 13: 120-124, 1996.
17. Hsueh WA: Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonists. Cur Opinion Pharmacol 2: 182-188, 2002.
18. Ruggeneti P, Perna A, Gheradi G y cols.: Renal function and requirement for dialysis in chronic nehropathy patients on long-term ramipril: REIN follow-up trial. Lancet 354: 359-364, 1998.
19. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J: Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (19): 1934-6, 2004.